BCM
RARE icon

Boreal Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Boreal Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.1K Hold
100
– – ﹤0.01% 443
2025
Q4 		$2.3K Hold
100
– – ﹤0.01% 461
2025
Q3 		$3.01K Hold
100
– – ﹤0.01% 465
2025
Q2 		$3.64K Buy
+100
New +$3.6K ﹤0.01% 415

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Boreal Capital Management's RARE Position: Q1 2026 in Review

Boreal Capital Management held its Ultragenyx Pharmaceutical (RARE) position steady in Q1 2026 at 100 shares worth $2.1K. The position accounts for ﹤0.01% of the portfolio, ranked #443.

Boreal Capital Management first reported a position in RARE in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.64K in Q2 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Boreal Capital Management held 100 shares of Ultragenyx Pharmaceutical worth $2.1K as of Q1 2026.
  • Boreal Capital Management left its Ultragenyx Pharmaceutical share count unchanged in Q1 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Boreal Capital Management's portfolio in Q1 2026, its #443 holding.
  • Boreal Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and has held it in 4 quarters since.
  • Boreal Capital Management's Ultragenyx Pharmaceutical position peaked at $3.64K in Q2 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Boreal Capital Management's 13F filing for Q1 2026, filed 14 May 2026.